Hideko Yamauchi

TL;DR: In this paper, a review examines IBC's unique clinical presentation, pathology, epidemiology, imaging, and biology and details current multidisciplinary management of the disease, which comprises systemic therapy, surgery, and radiation therapy.

TL;DR: Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission tomography-computed tomography, have improved the diagnosis and staging of inflammatory breast cancer, but the overall 5-year survival rate for patients with IBC remains very low.

TL;DR: Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer and further studies that include different patient populations and/or combinations with other agents might be performed at the lower dose levels.

TL;DR: ECD/her-2 levels are elevated in 35-40% of patients with metastatic breast cancer and are associated with a poorer prognosis in these patients, but no predictive role for ECD/HER-2 was identified, either for endocrine therapy or for anthracycline-based chemotherapy in the metastatic setting.

TL;DR: Several studies indicate that neoadjuvant chemotherapy with platinum-based regimens is effective for TNBC and is thus an important treatment option.